UBS raised the firm’s price target on Bristol Myers to $54 from $50 and keeps a Neutral rating on the shares ahead of the Q3 earnings report. The firm is 1% below consensus on revenues and sees a mixed performance from growth drivers, the analyst tells investors in a research note. UBS says focus will be on the Cobenfy launch dynamics following the recent approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- On drug prices, Harris pushes for cuts, Trump offers few specifics, NYTimes say
- AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
- Bristol Myers price target raised to $43 from $42 at Barclays
- Trump backs off support of controversial drug pricing plan, STAT reports
- Bristol Myers announces FDA approval of Opdivo for treatment of NSCLC
Questions or Comments about the article? Write to editor@tipranks.com